Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Tue, 27.08.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 27, 2024
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company’s Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the t [ … ]
Mon, 05.08.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 5, 2024
MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
MorphoSys AG today announced that it has completed the voluntary delisting of its shares from the Frankfurt Stock Exchange and its American Depositary Shares (“ADSs”) from the Nasdaq Global [ … ]
Wed, 24.04.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, April 24, 2024
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced th [ … ]
Thu, 11.04.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, April 11, 2024
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion
Shareholders benefit from attractive premium of 94% and 142% on the volume-weig [ … ]
Fri, 22.03.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 22, 2024
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the pro [ … ]
Wed, 13.03.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 13, 2024
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value
- Sold all tafasitamab rights worldwide to Incyte
- P [ … ]
Thu, 07.03.2024
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, March 07, 2024
Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
MorphoSys' Management team will host a con [ … ]
Mon, 05.02.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, February 5, 2024
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Tafasitamab sold to Incyte
Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of
€ 68.00 per share in cash
Shareholders benefi [ … ]
Tue, 30.01.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 30, 2024
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net prod [ … ]
Mon, 08.01.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 8, 2024
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. [ … ]